Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nachbagauer

Showing results (61-70 of 102) with videos related to

Pageof 11
Sort By:
Nature Medicine|June 5, 2019
Novel correlates of protection against pandemic H1N1 influenza A virus infectionSophia Ng, Raffael Nachbagauer, Angel Balmaseda, et al.
Nature Immunology|February 14, 2017
Defining the antibody cross-reactome directed against the influenza virus surface glycoproteinsRaffael Nachbagauer, Angela Choi, Ariana Hirsh, et al.
Science (New York, N.Y.)|October 26, 2019
Broadly protective human antibodies that target the active site of influenza virus neuraminidaseDaniel Stadlbauer, Xueyong Zhu, Meagan McMahon, et al.
Biomacromolecules|December 13, 2019
Synthetic Rhamnose Glycopolymer Cell-Surface Receptor for Endogenous Antibody RecruitmentRuben De Coen, Lutz Nuhn, Chamani Perera, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 14, 2019
Pre-existing Antineuraminidase Antibodies Are Associated With Shortened Duration of Influenza A(H1N1)pdm Virus Shedding and Illness in Naturally Infected AdultsHannah E Maier, Raffael Nachbagauer, Guillermina Kuan, et al.
NPJ Vaccines|March 20, 2021
AS03-adjuvanted H7N9 inactivated split virion vaccines induce cross-reactive and protective responses in ferretsDaniel Stadlbauer, Leon de Waal, Edith Beaulieu, et al.
The Journal of Infectious Diseases|April 6, 2017
Induction of Broadly Cross-Reactive Stalk-Specific Antibody Responses to Influenza Group 1 and Group 2 Hemagglutinins by Natural H7N9 Virus Infection in HumansLu Liu, Raffael Nachbagauer, Lingyan Zhu, et al.
Nature Communications|July 2, 2025
Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidaseAmanda K Rudman Spergel, Ivan T Lee, Kindra Koslovsky, et al.
The Journal of Infectious Diseases|June 27, 2024
Safety and Immunogenicity of mRNA-1010, an Investigational Seasonal Influenza Vaccine, in Healthy Adults: Final Results From a Phase 1/2 Randomized TrialJintanat Ananworanich, Ivan T Lee, David Ensz, et al.
Vaccine|February 7, 2025
A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adultsMieke Soens, Jintanat Ananworanich, Bryony Hicks, et al.
Pageof 11

Showing results (61-70 of 102) with videos related to

Sort By:
Pageof 11
Nature Medicine|June 5, 2019
Novel correlates of protection against pandemic H1N1 influenza A virus infectionSophia Ng, Raffael Nachbagauer, Angel Balmaseda, et al.
Nature Immunology|February 14, 2017
Defining the antibody cross-reactome directed against the influenza virus surface glycoproteinsRaffael Nachbagauer, Angela Choi, Ariana Hirsh, et al.
Science (New York, N.Y.)|October 26, 2019
Broadly protective human antibodies that target the active site of influenza virus neuraminidaseDaniel Stadlbauer, Xueyong Zhu, Meagan McMahon, et al.
Biomacromolecules|December 13, 2019
Synthetic Rhamnose Glycopolymer Cell-Surface Receptor for Endogenous Antibody RecruitmentRuben De Coen, Lutz Nuhn, Chamani Perera, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 14, 2019
Pre-existing Antineuraminidase Antibodies Are Associated With Shortened Duration of Influenza A(H1N1)pdm Virus Shedding and Illness in Naturally Infected AdultsHannah E Maier, Raffael Nachbagauer, Guillermina Kuan, et al.
NPJ Vaccines|March 20, 2021
AS03-adjuvanted H7N9 inactivated split virion vaccines induce cross-reactive and protective responses in ferretsDaniel Stadlbauer, Leon de Waal, Edith Beaulieu, et al.
The Journal of Infectious Diseases|April 6, 2017
Induction of Broadly Cross-Reactive Stalk-Specific Antibody Responses to Influenza Group 1 and Group 2 Hemagglutinins by Natural H7N9 Virus Infection in HumansLu Liu, Raffael Nachbagauer, Lingyan Zhu, et al.
Nature Communications|July 2, 2025
Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidaseAmanda K Rudman Spergel, Ivan T Lee, Kindra Koslovsky, et al.
The Journal of Infectious Diseases|June 27, 2024
Safety and Immunogenicity of mRNA-1010, an Investigational Seasonal Influenza Vaccine, in Healthy Adults: Final Results From a Phase 1/2 Randomized TrialJintanat Ananworanich, Ivan T Lee, David Ensz, et al.
Vaccine|February 7, 2025
A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adultsMieke Soens, Jintanat Ananworanich, Bryony Hicks, et al.
Pageof 11